By Rich Daly, chairman and CEO, Neuralstem
Transitions in pharma and biotech can take on many variations. However, experience offers guidance as to the key factors for success.
In my career, I’ve had the opportunity to work in just about every type of environment imaginable, starting with a growth company in my first life sciences job. That was followed by a startup; a large, mature pharma; a second startup; and three reorganizations (two large pharma and one biotech). Whether it’s moving from clinical to commercial stage, from one product to four, expanding the commercial footprint beyond the U.S., or leading a complete turnaround of a business, each required a transformational approach to ensure success at subsequent stages.